Deferiprone Market - Size, Share, Outlook, and Forecast till 2026

Deferiprone is an oral drug that functions as an iron chelator and indicated for treatment of thalassemia syndrome. Thalassemia is a form of hereditary anaemia due a defect in oxygen-carrying protein (hemoglobin) production, thus causing impairment in erythropoiesis, the production of new red blood cells. Symptoms associated with thalassemia include fatigue, weakness, paleness, and slow growth. Mild symptoms may not require treatment, however, severe forms require blood transfusions or a donor stem-cell transplant.

Deferiprone is a prescription medication known as an iron chelator, for treatment of high iron levels, especially for people who are required to receive frequent blood transfusions due to a genetic condition.

Deferiprone is indicated for thalassemia syndrome when first line chelation agents are not adequate to treat transfusional iron overload. The drug received license for use in Europe and Asia several years ago, while was awaiting approval in Canada and the U.S. It was approved for use in the U.S. and received FDA approval on October 14, 2011. The approval of the drug in major regions and almost every country of the world, in turn, is expected to increase the accessibility to several patients, thus boosting growth of the Deferiprone market.

Increasing prevalence of thalassemia among the populace is in turn, increasing the demand for Deferiprone drug. This is thus, expected to drive growth of the Deferiprone market.

However, side effects associated with consumption of Deferiprone, such as occurrence of agranulocytosis and neutropenia, which result in fatal infections, as well as hepatoxicity. Patients could also experience adverse effects such as gastrointestinal issues, including diarrhea, ulcer, nausea, and gastrointestinal disturbances. These factors in turn, pose as major restraints for growth of the Deferiprone market.

Deferiprone works in a simplified manner, as it binds with iron in the blood, further allowing for its excretion through urine, which would otherwise not have been possible through urine. The convenient removal of excess iron in the blood with the help of Deferiprone in turn, is increasing its adoption. Thus, the Deferiprone market is gaining significant traction, globally.

In May 2018, researchers at Rutgers University and Dartmouth College conducted a pilot study using Deferiprone and found that this is the first oral drug used to treat unrelated HIV eradicated infections, which was able to suppress the virus in patients during treatment and sustained its effects eight weeks from stopping of the treatment. The researchers found that as the topical anti-fungal medicine ciclopirox reactivates the altruistic suicide response of an HIV-infected cell, so does deferiprone work towards killing the HIV DNA it carries.

Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Deferiprone Market 2018, Forecast to 2023

Published Date : Jun 2018

Nerve damages can be caused by either blunt trauma, such as an impact from a fall or from traction injuries from motor vehicle accidents, or sharp trauma, such as direct cuts from a knife. Injury to a nerve can stop signals to and from the brain. Surgical nerve repair involves the exploration of the...

Global Deferiprone Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Published Date : Jun 2018

Nerve damages can be caused by either blunt trauma, such as an impact from a fall or from traction injuries from motor vehicle accidents, or sharp trauma, such as direct cuts from a knife. Injury to a nerve can stop signals to and from the brain. Surgical nerve repair involves the exploration of the...

Asia-Pacific Deferiprone Market Report 2017

Published Date : Dec 2017

In this report, the Asia-Pacific Deferiprone market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K MT),...

EMEA (Europe, Middle East and Africa) Deferiprone Market Report 2017

Published Date : Nov 2017

In this report, the EMEA Deferiprone market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), ...

Global and Chinese Deferiprone Market Outlook 2017-2022

Published Date : May 2017

The Deferiprone Market 2017 Report offers detailed analysis of the Deferiprone market over the last five years, and provides extensive market forecasts by region/country and sub sector. It covers the key technological and market trends in the Deferiprone market. It further lays out an analysis of th...

United States Deferiprone Market Report 2017

Published Date : Nov 2017

In this report, the United States Deferiprone market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: ...

Global Deferiprone Sales Market Report 2017

Published Date : Nov 2017

In this report, the global Deferiprone market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Mi...

United States Deferiprone Market by Manufacturers, States, Type and Application, Forecast to 2022

Published Date : Nov 2017

Deferiprone is an orally bioavailable bidentate ligand with iron chelating activity.1 It binds to iron in a 3:1 (ligand:iron) molar ratio and, thereby, is able to remove excess iron from the body. Deferiprone has been investigated for clinical use in diseases of systemic iron overload ...

Global Deferiprone Market Research Report 2017

Published Date : Nov 2017

In this report, the global Deferiprone market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, ...

North America Deferiprone Market by Manufacturers, Countries, Type and Application, Forecast to 2022

Published Date : Sep 2017

Deferiprone is an orally bioavailable bidentate ligand with iron chelating activity.1 It binds to iron in a 3:1 (ligand:iron) molar ratio and, thereby, is able to remove excess iron from the body. Deferiprone has been investigated for clinical use in diseases of systemic iron overload ...

 

Select Licence :

  • Single User : $4500
  • Multiple User : $7000
  • Corporate User : $10000

Happy To Assist You

Assist you at Worldwide Market Reports

We will be happy to help you find what you need. Please call us or write to us:

Worldwide Market Reports Benefits

Custom Research Solution

Talk to our research consultant to design an exclusive report as per your research needs.

Customer Fulfilment

We aim to fulfil client's research demands with tailored research solutions.

Quick Turnaround Time Reports

We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

360-degree Approach

We cover each industry from supply and demand side with an aim to provide a most holistic research study.